Efficacy of oregonin investigated by non-invasive evaluation in a B16 mouse melanoma model

Onseok Lee, Jaeyoung Kim, Young Wook Choi, Minwon Lee, Gyuman Park, Chil Hwan Oh

    Research output: Contribution to journalLetterpeer-review

    7 Citations (Scopus)


    Oregonin has been reported to act as a mediator of antibiosis, a liver-protective agent, an antioxidant, an anti-inflammatory agent, and to prevent cancer outbreaks. B16 melanoma cells were separated with trypsin-ethylenediaminetetraacetic acid, resuspended in 50 μl of phosphate-buffered saline and transplanted into the backs of 6- to 8-week-old male Balb/c nude mice through subcutaneous injection. Treatment doses of oregonin were administered three times weekly, for 30 days from the 11th day after transplantation of the melanoma cells, in each group. The study consisted of a control group, a dacarbazine group, an oregonin group and a dacarbazine + oregonin group. Measurements were taken before treatment and on the 5th, 7th, 10th and 15th days after treatment for each group. Based on survival rates after transplantation, the control group showed less than 50% survival after 20 days, while the treatment groups showed at least 50% survival up to the 41st day.

    Original languageEnglish
    Pages (from-to)842-844
    Number of pages3
    JournalExperimental Dermatology
    Issue number12
    Publication statusPublished - 2013 Dec 1


    • Calipers
    • Melanoma
    • Micro-PET/CT
    • Oregonin
    • Stereo image

    ASJC Scopus subject areas

    • Biochemistry
    • Molecular Biology
    • Dermatology


    Dive into the research topics of 'Efficacy of oregonin investigated by non-invasive evaluation in a B16 mouse melanoma model'. Together they form a unique fingerprint.

    Cite this